Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTX-MC138 · 1 trial · 1 indication
The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence of treatment-emergent adverse events (TEAEs).
proportion of subjects with a best response of CR, PR, or stable disease for at least 8 weeks per RECIST version 1.1.
| Arm | Type | Description |
|---|---|---|
| Dose level 1 | EXPERIMENTAL | 0.4 mg/kg of TTX-MC138 |
| Dose level 2 | EXPERIMENTAL | 0.8 mg/kg of TTX-MC138 |
| Dose level 3 | EXPERIMENTAL | 3.2 mg/kg of TTX-MC138 |
| Name | Type | Description |
|---|---|---|
| TTX-MC138 | DRUG | The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination. |
Inclusion Criteria: 1. Have histologically or cytologically confirmed diagnosis of relapsed/refractory metastatic or locally advanced solid tumor where no standard therapy exists, standard therapy has failed and have no available therapies with known clinical benefit. 2. Must have measurable or eva...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TTX-MC138 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced solid tumors who are at least 18 years old.
TTX-MC138 targets microRNA-10b, a microRNA involved in cancer progression. By targeting this molecule, the drug aims to interfere with pathways that may contribute to tumor growth and spread. This mechanism is being evaluated in a Phase 1 clinical trial for advanced solid tumors.
TTX-MC138 is being developed by TransCode Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced solid tumors. TransCode Therapeutics is publicly traded under the ticker symbol RNAZ.
TTX-MC138 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is active but not recruiting participants, and it is designed to study the drug in patients with advanced solid tumors.
TTX-MC138 is being studied in a single Phase 1 clinical trial with the identifier NCT06260774. The trial, titled 'Study of TTX-MC138 in Subjects With Advanced Solid Tumors,' is active but not recruiting and has an enrollment of 16 participants. It is being conducted in the United States.
Yes, TTX-MC138 has received orphan drug designation from the FDA. This designation is granted to drugs intended to treat rare diseases and may provide certain development incentives. The drug is still in Phase 1 clinical development and remains investigational.